David R Holmes, Shephal K Doshi, Saibal Kar, Matthew J Price, Jose M Sanchez, Horst Sievert, Miguel Valderrabano, Vivek Y Reddy
BACKGROUND: The risk-benefit ratio of left atrial appendage closure (LAAC) versus systemic therapy (warfarin) for prevention of stroke, systemic embolism, and cardiovascular death in nonvalvular atrial fibrillation (NVAF) requires continued evaluation. OBJECTIVES: This study sought to assess composite data regarding left atrial appendage closure (LAAC) in 2 randomized trials compared to warfarin for prevention of stroke, systemic embolism, and cardiovascular death in patients with nonvalvular AF...
June 23, 2015: Journal of the American College of Cardiology